Europe Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Country and Growth Forecast, 2022 - 2028

Europe Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Country and Growth Forecast, 2022 - 2028

The Europe Atopic Dermatitis Drugs Market would witness market growth of 9.0% CAGR during the forecast period (2022-2028).

Transepidermal water loss (TEWL) is far more common in atopic dermatitis sufferers than in healthy individuals, and xerotic portions of these patients' skin experience more TEWL than healthy skin does. Ceramide levels are noticeably lower in the epidermis' outermost layer. The lack of ceramide leads to the xerosis that is a hallmark of atopic dermatitis because ceramide stores water in the extracellular space of this horny layer.

The increased TEWL and decreased ceramide protection also allow for greater antigen penetration, and increasing infection rates, which can subsequently cause the release of pruritogenic, pro-inflammatory mediators by activating the cytokine cascade launched by the epidermis.

Patients with AD are more likely to develop other atopic conditions such as asthma and allergic rhinitis. According to clinical observations, patients can experience what has been dubbed the "atopic march," which is a progression from AD to the onset of asthma and allergic rhinitis.

The prevalence of allergic illnesses is a significant contributor to patient morbidity and healthcare utilization. Epidemiological research suggests that in many western nations, the prevalence of organ-specific allergy illnesses has increased in recent years. These disorders include allergic rhinitis and eczema. Geographic variations in the incidence of these illnesses in both children and adults6 are equally startling. Anaphylaxis and food allergies, among other systemic allergic disorders, appear to be on the rise over the past ten years.

The Germany market dominated the Europe Atopic Dermatitis Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,382.3 million by 2028.The UK market is estimated to grow a CAGR of 8.1% during (2022 - 2028). Additionally, The France market would experience a CAGR of 9.8% during (2022 - 2028).

Based on Route of Administration, the market is segmented into Injectable, Oral and Topical. Based on Class, the market is segmented into Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

• Injectable
• Oral
• Topical

• Biologics
• Calcineurin Inhibitors
• Corticosteroids
• PDE4 Inhibitors
• Others

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

• Pfizer Inc.
• Sanofi SA
• AbbVie Inc.
• Galderma S.A.
• Eli Lilly and Company
• Leo Pharma A/S
• Regeneron Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Novartis AG
• Incyte Corporation

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free